摘要： To evaluate the effect of statins for erectile dysfunction (ED), a systematic review of the literature was conducted in the Cochrane Library, Embase and PubMed from the inception of each database to June 2013. Only randomized controlled trials (RCTs) comparing treatment for ED with statins were identiifed. Placebo RCTs with the International Index of Erectile Function (IIEF) as the outcome measure were eligible for meta-analysis. A total of seven RCTs including two statins with a total of 586 patients strictly met our criteria for systematic review and ifve of them qualiifed for the meta-analysis. A meta-analysis using a random effects model showed that statins were associated with a signiifcant increase in IIEF-5 scores (mean difference (MD):3.27;95%conifdential interval (CI):1.51 to 5.02;P<0.01) and an overall improvement of lipid proifles including total cholesterol (MD:-1.08;95%CI:-1.68 to-0.48;P<0.01), low-density lipoprotein (LDL) cholesterol (MD:-1.43;95%CI:-2.07 to-0.79;P<0.01), high-density lipoprotein (HDL) cholesterol (MD:0.24;95%CI:0.13 to 0.35;P<0.01) and triglycerides (TGs) (MD:-0.55;95%CI:-0.61 to -0.48;P< 0.01). In summary, our study revealed positive consequences of these lipid-lowering drugs on erectile function, especially for nonresponders to phosphodiesterase type 5 inhibitors (PDE5Is). However, it has been reported that statin therapy may reduce levels of testosterone and aggravate symptoms of ED. Therefore, larger, well-designed RCTs are needed to investigate the double-edged role of statins in the treatment of ED.
-
生活方式对亚洲男性性激素、性活动以及老龄化的调节作用
-
70W和120W2微米激光汽化切除良性前列腺增生的体外对比研究
-
中国人类精子库捐精现状及应用:7年多中心回顾性研究
-
西地那非联合多沙唑嗪缓释剂治疗勃起功能障碍合并良性前列腺增生相关下尿路症状患者疗效的开放对照多中心临床评估
-
体重指数及血脂水平与血清前列腺特异抗原的关系:一组中国50岁以下人群的研究
-
血清PSA水平与非癌变前列腺组织体积的比值是接受前列腺癌根治术患者局部晚期前列腺癌生化复发的新指标
-
人精子纤维鞘内CABYR蛋白与AKAP3及Ropporin蛋白结合
-
芳香化酶(CYP19)基因变体同精子浓度和活性的关系
-
治疗前列腺癌的化疗新策略:一种新的Eg5抑制剂S-(methoxytrityl)-L-cysteine
-
ERβ基因RsaI多态性可能降低精子受精力及胚胎的发育潜能
